NZ596143A - Delivery devices and their uses with first dose capsules in body accessible to rumen fluid via first outlet and second dose capsule(s) retained over firt outlet - Google Patents

Delivery devices and their uses with first dose capsules in body accessible to rumen fluid via first outlet and second dose capsule(s) retained over firt outlet

Info

Publication number
NZ596143A
NZ596143A NZ59614305A NZ59614305A NZ596143A NZ 596143 A NZ596143 A NZ 596143A NZ 59614305 A NZ59614305 A NZ 59614305A NZ 59614305 A NZ59614305 A NZ 59614305A NZ 596143 A NZ596143 A NZ 596143A
Authority
NZ
New Zealand
Prior art keywords
outlet
dose
firt
fluid via
delivery devices
Prior art date
Application number
NZ59614305A
Inventor
Kevin George Green
Gary Robert Harrison
Barry William Axon
Brian Robert Duncan
Mitch Venning
David Chandler
Original Assignee
Argenta Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Mfg Ltd filed Critical Argenta Mfg Ltd
Priority to NZ59614305A priority Critical patent/NZ596143A/en
Publication of NZ596143A publication Critical patent/NZ596143A/en

Links

Landscapes

  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

A first dose consists of one or more actives housed in a body which are accessible to rumen fluid via a first outlet 23 (shown at lower end of drawing). A release arrangement retains a second dose 24 containing active(s) over the first outlet 23. A variable geometry structure (typically as a foldable wing) assists to retain the device in the rumen.
NZ59614305A 2005-09-09 2005-09-09 Delivery devices and their uses with first dose capsules in body accessible to rumen fluid via first outlet and second dose capsule(s) retained over firt outlet NZ596143A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ59614305A NZ596143A (en) 2005-09-09 2005-09-09 Delivery devices and their uses with first dose capsules in body accessible to rumen fluid via first outlet and second dose capsule(s) retained over firt outlet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ59614305A NZ596143A (en) 2005-09-09 2005-09-09 Delivery devices and their uses with first dose capsules in body accessible to rumen fluid via first outlet and second dose capsule(s) retained over firt outlet

Publications (1)

Publication Number Publication Date
NZ596143A true NZ596143A (en) 2012-08-31

Family

ID=46755270

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ59614305A NZ596143A (en) 2005-09-09 2005-09-09 Delivery devices and their uses with first dose capsules in body accessible to rumen fluid via first outlet and second dose capsule(s) retained over firt outlet

Country Status (1)

Country Link
NZ (1) NZ596143A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529310B2 (en) 2020-12-08 2022-12-20 Ruminant Biotech Corp Limited Devices and methods for delivery of substances to animals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529310B2 (en) 2020-12-08 2022-12-20 Ruminant Biotech Corp Limited Devices and methods for delivery of substances to animals

Similar Documents

Publication Publication Date Title
CL2007002526A1 (en) A MEDICINAL PRODUCT THAT INCLUDES, SEPARATE OR TOGETHER: A) A GLYCOPIRRON SALT; B) A BETA-2 ADRENO-RECEIVER AGONIST SELECTED FROM SALMETEROL AND FORMOTEROL; AND C) A CORTICOSTEROID; PHARMACEUTICAL KIT; AND USE IN THE TREATMENT OF AN INFL DISEASE
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
CA2807554C (en) Implantable therapeutic device
BRPI0815577A2 (en) FOXM1 PEPTIDE AND MEDICAL AGENT UNDERSTANDING THE SAME.
CL2014001029A1 (en) Oral solid pharmaceutical dosage form of extended release comprising a matrix formulation comprising an active agent in the form of a tablet or multiparticulate; active agent is an opioid analgesic; and use in the treatment of pain. (div. sun. 499-2012).
ATE527976T1 (en) DEVICE FOR STORAGE, IMMEDIATE PREPARATION AND ADMINISTRATION OF AN ACTIVE SUBSTANCE
WO2009158654A3 (en) Disposable infusion device with cannula port cover
CL2007001724A1 (en) USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
IN2012DN05228A (en)
EP1902663A4 (en) Apparatus for placing capsule type medical device, apparatus for placing capsule endoscope in the body and capsule type medical device for placement
WO2014102613A3 (en) Device for disposal and neutralization of pharmaceutical agents
MX2009000730A (en) Controlled release formulations and associated methods.
UA105210C2 (en) Anti-cancer vaccine and use thereof
EP1698267A4 (en) Capsule device for medical use
IL188732A (en) Use of ibuprofen and famotidine in the preparation of medicaments
AR084713A1 (en) LAGRIMAL PLUG CONTAINING DRUG FORMULATION
IL196394A0 (en) Implantable sustained drug delivery device for releasing active agents to the osteomeatal complex
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
BRPI0816236A2 (en) Cdh3 peptide and medicinal agent containing the same
WO2006133569A8 (en) Therapeutic polymeric pouch
IL195935A0 (en) 18-methyl-19-nor-androst-4-en 17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
PL1795186T5 (en) Flupirtin comprising medicament formulation with a controlled release of the active agent
USD579542S1 (en) Medical liquid administration device
IL174691A0 (en) Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 09 SEP 2015 BY AJ PARK

Effective date: 20130326

ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 09/09/2004

Effective date: 20130927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2016 BY AJ PARK

Effective date: 20150824

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2017 BY AJ PARK

Effective date: 20160901

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2018 BY AJ PARK

Effective date: 20170830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2019 BY AJ PARK

Effective date: 20180827

ASS Change of ownership

Owner name: ARGENTA INNOVATION LIMITED, NZ

Effective date: 20181127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2020 BY DENTONS NEW ZEALAND LIMITED

Effective date: 20190822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2021 BY DENTONS PATENT ATTORNEYS AUSTRALASIA LIMITED

Effective date: 20200901

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2022 BY DENTONS PATENT ATTORNEYS AUSTRALASIA LIMITED

Effective date: 20210907

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 SEP 2023 BY DENTONS PATENT ATTORNEYS AUSTRALASIA LIMITED

Effective date: 20220823

LAPS Patent lapsed